[{"_1":2,"_3":-5,"_4":-5},"loaderData",{"_5":6,"_7":8,"_9":10},"actionData","errors","root",{"_105":106,"_107":59},"routes/en-gate",{"_104":59},"en-item",{"_11":12},"item",{"_13":14,"_15":16,"_17":18,"_19":-5,"_20":-5,"_21":-5,"_22":23,"_24":25,"_26":27,"_28":29,"_30":27,"_31":32,"_33":34,"_35":36,"_37":38,"_39":40,"_41":-5,"_40":42,"_43":-5,"_44":-5,"_45":-5,"_46":47,"_48":49,"_50":-5,"_51":52,"_53":54,"_55":56,"_57":38,"_58":59,"_60":-5,"_61":62,"_63":64,"_65":38,"_66":38,"_67":68},"id","cn1ixxwyd504hs80i75158dfz","revision",1,"title","🚨 #ESMO26 Presidential 2 | SAFFRON Ph3","originalTitle","summary","reason","source",{"_13":98,"_79":99,"_100":101,"_102":38,"_103":-5},"links",{"_95":96,"_68":97},"publishedAt","2026-10-25T14:24:57.000Z","discoveredAt","2026-10-25T14:37:27.527Z","timelineAt","category","opinion","tags",[],"score",70,"selected",false,"channel","x","story",{"_87":49,"_88":49,"_89":-5,"_90":-5,"_91":92,"_93":94},"insight","digest","conferenceAbstracts","readingMode","full","author","OncUpdates","language","body",{"_83":-5,"_68":84,"_85":-5,"_86":59},"outline",[],"relatedStories",[],"indexable","markdownAvailable",true,"group","conference",{"_77":78,"_79":80,"_81":-5,"_82":-5},"engagement",{"_69":70,"_71":16,"_72":73,"_74":16,"_75":76},"posterIsAuthor","hasTranslation","bodyLanguage","original","heat",2,"likes","replies",0,"reposts","views",25,"slug","esmo-2026","name","ESMO Congress 2026","topic","reading","zh","

🚨 #ESMO26 Presidential 2 | SAFFRON Ph3

Osimertinib + savolitinib vs platinum–pemetrexed in EGFRm MET-OE and/or -AMP advanced #NSCLC post-osimertinib
✅ mPFS: 7.6 vs 5.4 mo
✅ mOS:17.8 vs 12.9 mo
✅ Median DoR: 9.7 vs 5.7 mo
⚠️Grade ≥3 TRAEs:40% vs 52%

#LCSM #EGFR #OncTwitter

","zhKind","complete","authorName","handle","avatarUrl","quoted","thread",[],"media",[],"aihot","/items/cn1ixxwyd504hs80i75158dfz","https://x.com/OncUpdates/status/2114362581473173973","esmo26-floor","x.com","kind","x_search","firstParty","iconUrl","ok","changelogVersion","2026-10-24T20:30","enEditionEnabled"]